Previous close | 0.7100 |
Open | 0.7250 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.7250 - 0.7400 |
52-week range | 0.3800 - 1.1500 |
Volume | |
Avg. volume | 34,790 |
Market cap | 26.896M |
Beta (5Y monthly) | 1.65 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.0300 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 2.88 |
DALLAS, March 18, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update.
DALLAS, December 01, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
DALLAS, November 13, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business update.